![Karl Anders Arne Linér](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karl Anders Arne Linér
Keine laufenden Positionen mehr
Profil
Mr. Karl Anders A.
Linér is Chief Auditor at Athera Biotechnologies AB.
Mr. Linér was previously employed as Auditor by RaySearch Laboratories AB.
Ehemalige bekannte Positionen von Karl Anders Arne Linér
Unternehmen | Position | Ende |
---|---|---|
Athera Biotechnologies AB
![]() Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Comptroller/Controller/Auditor | - |
RAYSEARCH LABORATORIES AB | Comptroller/Controller/Auditor | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
RAYSEARCH LABORATORIES AB | Technology Services |
Private Unternehmen | 1 |
---|---|
Athera Biotechnologies AB
![]() Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |